Patheon announces UK expansion and posts improved financials for fiscal 2013

By Gareth Macdonald

- Last updated on GMT

Patheon announces UK expansion
Patheon announces UK expansion

Related tags Pharmacology

Soon to merge CMO Patheon has increased solid dosage form production capacity at its site in the UK and posted an improved set of preliminary results for the financial year.

The contract manufacturing organisation (CMO) has added automated capsule filling, tablet compression and coating capabilities at its facility in Milton Park, Oxford as part of what site manager Jon Sutch said was an effort to offer a wider range of dosage forms.

The UK investment – which comes three years after Patheon ramped up its capacity to produce capsules and other oral dosage forms at its sister manufacturing facility in Bourgoin, France​ – is designed to establish a stand-alone development centre.

News of the UK investment also comes just a few weeks it was announced that Patheon would become a private company and merge with the pharmaceutical products contracting business of Royal DSM​.

At the time DSM CFO Ralph-Dieter Schwalb highlighted Patheon’s capabilities in drug development coupled with its capsules business – strengthened buy its acquisition of Banner Pharmacaps​ in 2012 – would be the core focus for the new combined company.

The UK investment coincides with the publication of Patheon’s preliminary financial results for the fiscal year which, although not the final figures, suggest that the CMO has performed better in the last 12 months than it did in fiscal 2012.

Patheon reported revenues of $1.02bn, $876.8m of which was generated by its CMO business while the remaining $146.3m coming from its pharmaceutical development services operations.

In fiscal 2012 Patheon’s revenues were $700m, with CMO services bringing in $610m and development services contributing $138.4m.

Similarly Patheon seems to have reduced its losses in 2013, posting a deficit of $38.5m from continuing operations, which is a significant reduction on the $106m shortfall it recorded in the year-earlier 12 months.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more